Ticker
AGLE

Price
27.60
Stock movement down
-0.06 (-0.22%)
Company name
Aeglea Bio Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
72.20M
Ent value
58.17M
Price/Sales
31.00
Price/Book
1.44
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-11.19%
1 year return
116.47%
3 year return
-45.84%
5 year return
-33.53%
10 year return
-
Last updated: 2024-03-28

DIVIDENDS

AGLE does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales31.00
Price to Book1.44
EV to Sales24.98

FINANCIALS

Per share

Loading...
Per share data
Current share count2.62M
EPS (TTM)-24.86
FCF per share (TTM)-23.79

Income statement

Loading...
Income statement data
Revenue (TTM)2.33M
Gross profit (TTM)2.16M
Operating income (TTM)-84.78M
Net income (TTM)-83.81M
EPS (TTM)-24.86
EPS (1y forward)-17.00

Margins

Loading...
Margins data
Gross margin (TTM)92.79%
Operating margin (TTM)-3640.23%
Profit margin (TTM)-3598.75%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash34.86M
Net receivables0.00
Total current assets62.26M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets71.14M
Accounts payable677.00K
Short/Current long term debt4.63M
Total current liabilities14.66M
Total liabilities20.84M
Shareholder's equity50.30M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-80.14M
Capital expenditures (TTM)39.00K
Free cash flow (TTM)-80.18M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-166.61%
Return on Assets-117.81%
Return on Invested Capital-164.57%
Cash Return on Invested Capital-157.44%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open26.71
Daily high28.09
Daily low26.60
Daily Volume411K
All-time high299.75
1y analyst estimate62.50
Beta1.71
EPS (TTM)-24.86
Dividend per share-
Ex-div date-
Next earnings date9 May 2024

Downside potential

Loading...
Downside potential data
AGLES&P500
Current price drop from All-time high-90.79%-0.08%
Highest price drop-99.11%-56.47%
Date of highest drop21 Jun 20239 Mar 2009
Avg drop from high-54.45%-11.36%
Avg time to new high1966 days13 days
Max time to new high1965 days1805 days
COMPANY DETAILS
AGLE (Aeglea Bio Therapeutics Inc) company logo
Marketcap
72.20M
Marketcap category
Small-cap
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Employees
69
Investor relations
-
SEC filings
CEO
Anthony G. Quinn
Country
USA
City
Austin
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner